Setup

Harrow (HROW) is a specialty ophthalmic pharma whose Q1 2026 10-Q filed May 11 broke all three pillars of its bull thesis simultaneously. Pre-print consensus was 100% Buy; sell-side estimates have not reset, and credit ratings (B3/B- Stable) were affirmed in late March before the print. The disclosed numbers — and a generalizable pattern they reveal — create a verifiable gap between what the filing shows and how the market is positioned.

What the filing says

• IHEEZO collapse. Q1 2026 revenue $1.851M vs ≈$20M+ quarterly run-rate in H2 2025. -91% BEFORE the official 3/31/26 ASC pass-through expiry. Demand destruction occurred within Q1 — providers switched to generic local anesthetics (lidocaine/tetracaine, $1-2/dose) weeks ahead of the cliff. Management addressed this with one euphemistic clause: "change in our customer mix, offset by a decrease in IHEEZO volume." No quantification, no Q2 guidance.
• VEVYE flat. $20.947M Q1 2026 vs $21.516M Q1 2025 (-2.6% YoY). Coverage wins are increasing gross-to-net deductions; net revenue per unit is declining as payer mix shifts. The "on road to nine figures" CEO framing implies $100M+ annualized — actual $84M annualized.
• Compounding (ImprimisRx) -33% YoY. $13.499M Q1 with $343K segment contribution (vs $4.962M Q1 2025). The cash cow is effectively gone.
• P&L damage. Operating loss $(22.1M) vs $(11.2M) Q1 2025 — doubled YoY. Operating cash burn $(9.0M) vs +$19.7M — a $29M YoY swing. Cash $94.6M but $48.5M came from a March debt raise. True economic burn ≈$27M/quarter.
• Debt structure. $300M senior notes at 8.625% = $25.9M/yr interest. Interest coverage 1.18x against negative operating income.
• New MD&A language. First-time mention: "We may consider the sale of certain assets including, but not limited to, part of, or all of, our investments and any of our consolidated subsidiaries." Possible ImprimisRx divestiture signal.
• No 10b5-1 plans adopted by any officer in Q1 2026.

Set against comparable cases, the IHEEZO collapse establishes a pattern. LNTH PYLARIFY (TPT expired Dec 2024) declined -6.5% over a full post-expiry year. TLX Illuccix (TPT expired June 2025) grew dose volume +3% in its first MUC-pricing quarter. The discriminator is procedural fungibility: products where providers can substitute generic alternatives at zero clinical workflow change collapse pre-cliff (IHEEZO-pattern); clinically necessary products with only within-class substitutes see ASP compression with volumes preserved (PYLARIFY-pattern).

TRIESENCE — HROW's other pass-through product (preservative-free triamcinolone, expires April 2028) — has generic triamcinolone alternatives and compounded preservative-free substitutes available. It fits the IHEEZO profile, not the PYLARIFY profile. A second cliff is coming late 2027 / early 2028.

What the market thinks

• RSI 19.1, down -19% in the week post-print.
• Forward P/E 11.66 (sell-side has not reset estimates).
• 100% sell-side Buy consensus.
• Bonds B3/B- Stable, affirmed late March 2026 BEFORE the Q1 print.
• Short interest 19.4%, days-to-cover 13.2.
• Jan 2027 options OI 33,729 — concentrated capital structure for resolution.
• Put IV > Call IV by 2.6% (anomaly); OTM puts +25.7% skew, OTM calls +34% skew (binary-event positioning).

Market-implied probabilities (Jan 2027 puts) vs probability-weighted scenarios from the filing data:

The gap is widest in the moderate-distress strikes ($18-25), not the tails. The market is pricing HROW as 70-80% likely to hold above $23; filing data implies 50-50.

Why the gap exists

• No model for the latent factor. The CMS pass-through fungibility discriminator is not a covariate in any sell-side model. Standard practice treats all TPT expirations as gentle linear step-downs. The IHEEZO Q1 print is the first empirical disconfirmation.
• Bond pricing lag. Credit always lags equity; at 1.18x interest coverage with persistent operating burn, the B3/B- Stable rating is mathematically stale.
• Sector tailwind absorbs the noise. Specialty ophthalmic peers (BLCO, TARS, STAA, EYPT) all up YoY mask HROW's idiosyncratic deterioration in basket-level monitoring.
• Squeeze positioning absorbs bear flow (19% SI, 13 DTC).
• Sell-side anchored to CCO RSU $920M FY2027 branded revenue target. Q1 2026 branded annualized = $123M; reaching $920M requires 7.5x growth in 7 quarters. The math is not survivable, but no analyst has reset estimates.

Risks

Catalysts

• Aug 10, 2026 — Q2 2026 earnings. Primary catalyst. IHEEZO Q2 print resolves the tracked prediction; VEVYE trajectory and any ImprimisRx process commentary at stake.
• Now → Aug. Sell-side downgrade cascade likely; first downgrade resets the anchor.
• Jun-Sep 2026. Possible 8-K on ImprimisRx process (sale or process collapse).
• Sep-Nov 2026. Bond rating action if Q2 weak; first bear-side initiations.
• Nov 2026 — Q3 2026 earnings. Confirms or denies Q2 trajectory.
• H2 2027. TRIESENCE pre-cliff demand softness begins under fungibility model.
• Apr 2028. TRIESENCE pass-through expires.

What would change our mind

• IHEEZO Q2 2026 prints >$5M (rebound, not structural collapse).
• VEVYE Q2 prints >$26M (re-acceleration).
• ImprimisRx sold for $150M+ unencumbered.
• HROW 8.625% notes hold ≥98 through end-Q3 2026 (credit market doesn't reprice).
• Insider Form 4 open-market purchases at current levels.
• An empirical TPT case emerges that violates the fungibility discriminator — a clinically necessary product that collapses pre-cliff, or a fungible product that holds revenue post-cliff.